Results 131 to 140 of about 6,944 (246)
GLP-1RAs for the treatment of obesity in women after menopause
Maturitas, 2022 Paschou, S.A. +4 more
openaire +3 more sources
Diabetes, Obesity and Metabolism, Volume 28, Issue 4, Page 2806-2814, April 2026.Abstract Aims To evaluate the cardiovascular efficacy of glucagon‐like peptide‐1 receptor agonists (GLP‐1RAs) in Asian, Black or African American, and White populations, and to assess whether the magnitude of cardiovascular risk reduction differs across these populations.
Masashi Hasebe +4 more
wiley +1 more source
Diabetes, Metabolic Syndrome and Obesity, 2015 Leigh MacConell,1 Kate Gurney,2 Jaret Malloy,1 Ming Zhou,3 Orville Kolterman4 1Clinical Development, Bristol-Myers Squibb, San Diego, CA, USA; 2Medical Writing, Bristol-Myers Squibb, San Diego, CA, USA; 3Biostatistics, Bristol-Myers Squibb, Princeton, NJ,
MacConell L +4 more
doaj
Diabetes, Obesity and Metabolism, Volume 28, Issue 4, Page 2953-2961, April 2026.Abstract Objective People with chronic kidney disease (CKD) and diabetes are at high risk of cardiovascular disease (CVD). Aortic pulse wave velocity (Ao‐PWV) is an independent predictor of CVD. Cardiovascular outcome trials (CVOTs) with glucagon like peptide‐1 receptor agonist (GLP‐1 RA) class demonstrate notable differences, with lixisenatide having ...
Nikolaos Fountoulakis +8 more
wiley +1 more source
Diabetes, Obesity and Metabolism, Volume 28, Issue 4, Page 3033-3043, April 2026.Abstract Aims We investigated whether dipeptidyl peptidase‐4 inhibitor (DPP‐4i) use was associated with a higher risk of acute pancreatitis compared with sodium–glucose cotransporter 2 inhibitor (SGLT2i) use in antidiabetic medication‐naïve individuals.
Takashi Tatewaki +3 more
wiley +1 more source
Diabetes, Obesity and Metabolism, Volume 28, Issue 4, Page 3137-3145, April 2026.Abstract Aim Heart failure with preserved ejection fraction (HFpEF) presents a therapeutic challenge, characterised by a paucity of validated treatments. Emerging data suggest that targeting adiposity is central to HFpEF pathogenesis. We conducted an updated network meta‐analysis to compare the efficacy of emerging and established HFpEF therapies ...
Szu‐Han Chen +7 more
wiley +1 more source
The Latest topics of Standards of Care in Diabetes 2025: Focusing on GLP-1RA [PDF]
Hiroshi Bando, Michael Wood, Koji Ebe
openalex +1 more source
Response to Comment on Gan et al. Efficacy of Modern Diabetes Treatments DPP-4i, SGLT-2i, and GLP-1RA in White and Asian Patients With Diabetes: A Systematic Review and Meta-analysis of Randomized Controlled Trials. Diabetes Care 2020;43:1948–1957 [PDF]
, 2020 Sushrima Gan +6 more
openalex +1 more source
An oral glucose tolerance test in pregnancy and its association with future cardiovascular diseases
Diabetes, Obesity and Metabolism, Volume 28, Issue 4, Page 3146-3154, April 2026.Abstract Aims/hypothesis Gestational diabetes and abnormal 100‐g oral glucose tolerance test (OGTT) results in pregnancy are associated with type 2 diabetes, but their relationship with cardiovascular disease (CVD) is less clear. We evaluated the risk of CVD according to the number of abnormal OGTT values during pregnancy.
Tal Schiller +7 more
wiley +1 more source